Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology
Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sabino De Placido, Antonio Giordano(University of Siena), Roberta Maria Pennacchio(University of Naples Federico II), Alessandro Esposito(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesca Caputo, Mario Giuliano(Regione Campania), Lucrezia Silvestro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Emilia Montagna, Giuseppe Cancello, Luigia Zinno, Luca Malorni(Azienda Usl Toscana Centro), Antonello Accurso(University of Naples Federico II)
Cited by 49
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Curcumin and Cancer
|Nutrients|2019|977
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Role of p53 in the Regulation of Cellular Senescence
|Biomolecules|2020|605